BioMedNewsBreaks — MetAlert Inc. (MLRT) Engages Veteran Firm as Financial Advisor to Assist with Growth Strategy, Corporate Development Initiatives

MetAlert (OTC: MLRT), a pioneer in location-sensitive, health-monitoring devices and wearable technology products for remote patient monitoring, announced that Joseph Gunnar & Co. LLC will serve as the company’s financial advisor. According to the announcement, Joseph Gunnar will support the company as it communicates its growth strategy to the investment community; the firm will also provide advice on possible financing alternatives and acquisitions and will assist as MetAlert moves toward uplisting on a national exchange. Joseph Gunnar officials called MetAlert’s vision “compelling” and noted the company’s ability to leverage its extensive IP portfolio to bring valuable tech solutions to the global marketplace. Joseph Gunnar anticipates focusing the “full force” of its financial and business development teams on MetAlert’s financing and operational goals. A full-service boutique investment banking, securities and wealth management firm, Joseph Gunnar services include private wealth management, global institutional equity, fixed-income and derivatives sales and trading, equity research and advisory insight. The firm’s client list includes a diverse range of corporate clients, institutional investors and high-net-worth individuals. “MetAlert is approaching the inflection point of its growth curve by its ability to sell a multitude of products and services to a broader audience, which will result in greater revenue per user,” said MetAlert CEO Patrick Bertagna in the press release. “We are thrilled to align with a proven advisor like Joseph Gunnar in our quest to maximize shareholder value.”

To view the full press release, visit https://ibn.fm/KV9Xd

About MetAlert Inc.

MetAlert, a pioneer in smart, mobile, and wearable tracking and recovery location-based solutions, is supported through a proprietary IoT enterprise monitoring platform and intellectual property portfolio. The company offers a global end-to-end solution of hardware, software and connectivity and develops two-way GPS tracking technologies, which seamlessly integrate with consumer products and enterprise applications. Utilizing the latest in miniaturized, low-power consumption GPS, cellular, RF, NFC and BLE technology, MetAlert products enable subscribers to track in real time the whereabouts of people or high-value assets. Known for its game-changing and award-winning patented GPS SmartSole — think Dr. Scholl’s meets LoJack — the world’s first invisible, wearable, technology-tracking device created for those at risk of wandering due to Alzheimer’s, dementia, autism or traumatic brain injury. MetAlert’s business model is built around technology innovation, and the company holds dozens of patents, with many issued patents in the area of GPS tracking. MetAlert has international distributors servicing customers across the globe with subscribers in more than 40 countries; MetAlert is also a U.S. military government contractor. Other customers include public health authorities and municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes and consumers. For more information about this company, please visit www.MetAlert.com

NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork